HRTIS.HE
Herantis Pharma Oyj [HRTIS.HE] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
HRTIS.HE Stock Summary
Top 10 Correlated ETFs
HRTIS.HE
Top 10 Correlated Stocks
HRTIS.HE
In the News
HRTIS.HE Financial details
Company Rating
-
Market Cap
28.22M
Income
-3.39M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
10
Optionable
No
Shortable
Yes
Earnings
06 Mar 2024
P/E
-2.2
Forward P/E
-
PEG
0.35
P/S
-
P/B
-3.89
P/C
-
P/FCF
-0.04
Quick Ratio
3.15
Current Ratio
3.28
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.27
EPS next Y
-
EPS next Q
-
EPS this Y
-102.23%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-209.09%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-2%
ROE
297%
ROC
-0.02%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.17-2.32
52W High
-11%
52W Low
+78%
RSI
49
Rel Volume
3.29
Avg Volume
7.16K
Volume
23.59K
Perf Week
4.71%
Perf Month
9.88%
Perf Quarter
-16.43%
Perf Half Y
-19.09%
-
-
-
-
Beta
0.308
-
-
Volatility
0.04%, 0.06%
Prev Close
2.89%
Price
1.78
Change
2.89%
Company Profile
- Volume Average 7.16K
- Market Capitalization 28.22M
- Employee 10
- CEO Dr. Antti Vuolanto D.Sc. (Tech)
- Headquarters Espoo,FI
- IPO Date 2014-06-11
-
Website
https://www.herantis.com 
Herantis Pharma Oyj, a biotech company, engages in the development of disease-modifying CDNF-based therapies for Parkinson's disease (PD). Its lead product in pipeline includes HER-096, an advanced small and synthetic chemical peptidomimetic version of the active parent as the preclinical xCDNF candidate for the treatment of PD and other neurodegenerative diseases; and recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF), a biological protein that is in Phase I study in patients with PD. The company was incorporated in 2008 and is based in Espoo, Finland.
